Breaking News

Celyad Successfully Produces CYAD-01 with OptimAb Mfg. Process

Doses first patient in Phase I trial with CYAD-01, an investigational CAR-T therapy being evaluated in AML

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, has successfully administered CYAD-01 produced with the OptimAb manufacturing process to a patient in the Phase I DEPLETHINK trial.   Jean-Pierre Latere, chief operating officer of Celyad, said, “The dosing of the first patient with CYAD-01 manufactured with the OptimAb process marks another important milestone for our company. The OptimAb manufacturing process has shown exciting activi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters